Reduced Microbiome Diversity in Myalgic Encephalopathy/CFS

Share this content:
Reduced Microbiome Diversity in Myalgic Encephalopathy/CFS
Reduced Microbiome Diversity in Myalgic Encephalopathy/CFS

FRIDAY, July 8, 2016 (HealthDay News) -- Patients with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) have reduced diversity and altered composition of the gut microbiome, according to a study published online June 23 in Microbiome.

Ludovic Giloteaux, Ph.D., from Cornell University in Ithaca, New York, and colleagues profiled gut microbial diversity by sequencing 16S ribosomal ribonucleic acid (rRNA) genes from stool and inflammatory markers from serum in 48 ME/CFS cases and 39 controls. Levels of C-reactive protein, intestinal fatty acid-binding protein, lipopolysaccharide (LPS), LPS-binding protein (LBP), and soluble CD14 (sCD14) in the blood were examined.

The researchers found that levels of LPS, LBP, and sCD14 were elevated in ME/CFS patients. Differences were identified between the gut microbiomes of ME/CFS individuals and controls based on deep sequencing of bacterial rRNA markers. Bacterial diversity was reduced in cases, with a decrease in the relative abundance and diversity of Firmicutes species. Less diversity was seen in the patient cohort, as were increases and decreases in specific species often described as pro- and anti-inflammatory, respectively. Individuals were correctly classified as ME/CFS using a machine learning approach trained on the data obtained from 16S rRNA and inflammatory markers, with 82.93 percent cross-validation accuracy.

"Our results indicate dysbiosis of the gut microbiota in this disease and further suggest an increased incidence of microbial translocation, which may play a role in inflammatory symptoms in ME/CFS," the authors write.

Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Bavencio for Merkel Cell Carcinoma

FDA Approves Bavencio for Merkel Cell Carcinoma

Drug targets the PD-1/PD-L1 pathway; first sanctioned treatment in the United States

Heterogeneous Association for Alcohol, CVD Presentation

Heterogeneous Association for Alcohol, CVD Presentation

Non-drinking linked to increased risks of unstable angina, MI, heart failure, ischemic stroke, PAD, AAA

Mobile App Cuts In-Person Visits After Breast Reconstruction

Mobile App Cuts In-Person Visits After Breast Reconstruction

Number of visits down, increase in e-mails to doctors for ambulatory patients undergoing breast recon

is free, fast, and customized just for you!

Already a member?

Sign In Now »